What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Type 2 diabetes
- Diabetes mellitus
His primary areas of study are Type 2 diabetes, Internal medicine, Endocrinology, Diabetes mellitus and Placebo.
He combines subjects such as Metformin, Insulin, Glycemic and Randomized controlled trial with his study of Type 2 diabetes.
His Randomized controlled trial research also works with subjects such as
- Tolerability which intersects with area such as Vildagliptin,
- Saxagliptin which intersects with area such as Cohort.
In his research, Postprandial is intimately related to Lixisenatide, which falls under the overarching field of Internal medicine.
In Endocrinology, Julio Rosenstock works on issues like Gastroenterology, which are connected to Weight gain and Colesevelam.
His work focuses on many connections between Diabetes mellitus and other disciplines, such as Urology, that overlap with his field of interest in Insulin lispro, Bedtime and Oral administration.
His most cited work include:
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (2111 citations)
- The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients (1313 citations)
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (1233 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Type 2 diabetes, Diabetes mellitus, Endocrinology and Insulin.
The Internal medicine study combines topics in areas such as Gastroenterology and Placebo.
His Type 2 diabetes research incorporates elements of Metformin, Urology, Randomized controlled trial, Adverse effect and Postprandial.
His work carried out in the field of Diabetes mellitus brings together such families of science as Surgery and Weight loss.
His research ties Glucagon-like peptide 1 receptor and Endocrinology together.
His work deals with themes such as Empagliflozin and Type 1 diabetes, which intersect with Insulin.
He most often published in these fields:
- Internal medicine (71.60%)
- Type 2 diabetes (63.44%)
- Diabetes mellitus (48.94%)
What were the highlights of his more recent work (between 2018-2021)?
- Type 2 diabetes (63.44%)
- Internal medicine (71.60%)
- Diabetes mellitus (48.94%)
In recent papers he was focusing on the following fields of study:
Julio Rosenstock mainly investigates Type 2 diabetes, Internal medicine, Diabetes mellitus, Randomized controlled trial and Insulin.
The concepts of his Type 2 diabetes study are interwoven with issues in Metformin, Kidney disease, Urology, Glucagon-like peptide 1 receptor and Glycemic.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Placebo and Semaglutide.
His study brings together the fields of Clinical endpoint and Diabetes mellitus.
His Randomized controlled trial study combines topics in areas such as Liraglutide, Clinical trial, Incidence, Intensive care medicine and Pharmacotherapy.
His Insulin study improves the overall literature in Endocrinology.
Between 2018 and 2021, his most popular works were:
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. (88 citations)
- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA (86 citations)
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes (72 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
